WE ARE SUSAN G. KOMEN®. WE ARE A FORCE UNITED BY A PROMISE TO END BREAST CANCER FOREVER. FOR OVER 30 YEARS WE’VE LED THE WAY FUNDING GROUNDBREAKING RESEARCH, COMMUNITY HEALTH INITIATIVES AND ADVOCACY PROGRAMS IN LOCAL COMMUNITIES ACROSS THE U.S. AND IN MORE THAN 30 COUNTRIES. WE WILL CONTINUE PUSHING FOR PROGRESS TO END BREAST CANCER EVERY DAY, UNTIL IT’S A THING OF THE PAST.
WE ARE SUSAN G. KOMEN®. WE ARE A FORCE UNITED BY A PROMISE TO END BREAST CANCER FOREVER. FOR OVER 30 YEARS WE’VE LED THE WAY FUNDING GROUNDBREAKING RESEARCH, COMMUNITY HEALTH INITIATIVES AND ADVOCACY PROGRAMS IN LOCAL COMMUNITIES ACROSS THE U.S. AND IN MORE THAN 30 COUNTRIES. WE WILL CONTINUE PUSHING FOR PROGRESS TO END BREAST CANCER EVERY DAY, UNTIL IT’S A THING OF THE PAST.

KOMEN COMMITMENT
INVESTING BILLIONS TO FIGHT BREAST CANCER.

Total amount invested

SINCE 1982: $2.5 billion+

In FY 2013, 83 cents of every dollar was invested directly in programs that further our mission. For the ninth straight year more than 80% of funds has been devoted to mission programs.

MAKING A DIFFERENCE IN THE COMMUNITY.

Amount invested in community programs

SINCE 1982: $1.5 billion+

In FY 2013:
$217 million+

Nearly $145m of our community outreach funds in FY 2013 was invested by our Affiliate Network in their local communities.

500,000+ breast screenings for low-income and uninsured women were paid for by Komen in 2012.

50,000+ women in 2012 received financial aid and psychosocial support provided by Komen programs.

MAKING A DIFFERENCE IN THE LAB.

Amount invested in research

SINCE 1982: $800 million+

In FY 2013:
$49.5 million

124 new research grants were funded by Komen in FY 2013.
Since our inception, the five-year relative survival rate for early-stage breast cancer has risen from 74 percent to 99 percent.
To our Komen family,

In this 2013 annual report covering our fiscal year April 1, 2012-March 31, 2013, Susan G. Komen commemorates the 30th anniversary of our founding. In three decades, we have grown from a promise between two sisters to become the world’s largest breast cancer organization, making significant contributions in a global fight against a terrible disease.

There have been many encouraging milestones in our decades-long fight against breast cancer.

Since our inception, the five-year relative survival rate for early-stage breast cancer has risen from 74 percent to 99 percent. Breast cancer mortality rates have dropped by 34 percent since 1990 in the U.S., and today, there are more treatments and support – and more hope – for women and men with metastatic and aggressive disease.

We are perhaps most proud of our community of breast cancer survivors, families, partners, donors and volunteers who share our passion to end breast cancer forever.

Our community has helped fund thousands of programs in the U.S., and 30 other countries around the world, including more than $800 million to date to support breast cancer research – more than any other non-profit.

We fund the medical center where a woman gets treatment, and the community program that provides groceries, wigs or medical supplies.

We stand up for breast cancer patients in Congress and state capitols, fighting for research funding and access to timely, high quality treatment for low-income and medically underserved individuals.

We fund the laboratories and clinics working every day to find better treatments – and cures – for breast cancer.

We have achieved a great deal in our 30 years. We have met with presidents, we’ve turned the Pyramids pink, and we’ve helped change breast cancer from a disease that couldn’t be mentioned to a movement that can’t be stopped.

In the fiscal year April 1, 2012-March 31, 2013, we, like many other non-profits, continued to work through the reality of a recovering economy and increased competition for donor dollars, as well as issues unique to our organization. That did not deter us, and the good work continued. From the Global Women’s Cancer Summit in Washington, to the wrestling arenas of the WWE, to mainland China and rural Wyoming, to research labs, and to the halls of Congress, we have advocated, educated, funded community organizations, forged innovative partnerships and helped spur scientific breakthroughs.

In this year’s report we’ll highlight some key events and achievements, from both 2013 and our three decades of history.

We will not rest as long as breast cancer remains the leading cause of cancer death among women worldwide. In the years ahead, we will continue our work to decrease unacceptable disparities in cancer care and outcomes. We will fund programs to understand and address the needs of specific populations, such as minority women, women under 40, rural women, and low-income, uninsured and low-resource women. We will also continue our strong focus on cutting-edge breast cancer research, with the aim of decreasing the incidence and mortality of all types of breast cancer, including the most aggressive forms.

As we celebrate 30 years, we press forward in our fight.

Thank you for your past and continuing support.

Linda Custard
Chair, Board of Directors*

*Mrs. Custard became Komen Board Chair in May of 2013.
Meet Jessica Winkler, a breast cancer survivor. She’s an optimistic, hard-working 30-something, dedicated to saving lives. At Susan G. Komen, so are we.

Around the time Jessica was born, Susan G. Komen began its fight against breast cancer. Since our founding in 1982, we have invested more than $2.5 billion in lifesaving programs and game-changing research.
One of our Komen-funded programs would prove critical for Jessica, who was diagnosed with breast cancer on her 28th birthday but as a student had no insurance and little money. Through a Komen grant to her local medical center, Jessica gained access to navigation and treatment assistance programs that led to her obtaining health insurance that covered her treatments.

**TODAY, JESSICA HAS NO SIGNS OF BREAST CANCER** and will graduate from Stony Brook University School of Nursing. Her goal: to become a nurse practitioner helping patients deal with the challenges of cancer.

**IN THREE DECADES, AMAZING THINGS CAN HAPPEN.** A young woman can grow up, beat breast cancer and devote her life to helping others. An organization can devote itself to fighting breast cancer and, over time, make a real difference in the lives of millions of men and women around the world.

Along the way, this same organization will help educate, screen, provide treatment support, and fund more breast cancer research than any other non-profit.

**WHERE WILL THE NEXT 30 YEARS TAKE US?** Like Jessica, Susan G. Komen is focused on what we can do in the years ahead to continue to make a difference.
Survivors inspire us. Everything we have done throughout our 30 years — our community grants, our corporate partnerships, our advocacy and education efforts, our research support — is directed to helping breast cancer patients and their loved ones.

“I thought my life was over at 24 years old.”  
Marisol Guerrero  
Breast Cancer Survivor

Marisol Guerrero thought her breast cancer diagnosis at 24 was a death sentence. “I had just graduated out of college. I didn’t have insurance. I didn’t have the money...I was a single mom ...I thought my life was over.” A Susan G. Komen grant provided financial assistance for her treatment. Today, she shows no evidence of cancer and helps others by leading a Susan G. Komen Race for the Cure team in Houston, Texas.

“I found myself on the other side of the conversation I’ve had with many patients.”  
Dr. Michelle Gaskins-Craig  
Breast Cancer Survivor

Michelle Gaskins-Craig grew up in an economically disadvantaged community in Southeast Washington, D.C., and has spent 25 years serving her community as a family doctor. When she was 41, she was diagnosed with stage II breast cancer. “I found myself on the other side of the conversation I’ve had with many patients.” Her experience reinforced for her the importance of patient-centered and culturally competent health care. Dr. Gaskins-Craig continues to serve her community through the DC Pink Divas, a Komen-funded community-based patient navigation and outreach program. She is the Susan G. Komen Global Race for the Cure 2013 Survivor of the Year.

---

1980
Susan G. Komen dies of breast cancer at the age of 36. Before she dies, she asks her sister, Nancy G. Brinker, to promise to end the disease.

1982
Nancy Brinker founds the Susan G. Komen Breast Cancer Foundation in Susan’s memory.

1983
First Susan G. Komen Race for the Cure® is held in Dallas, Texas, with 800 participants.

1989
Komen National Toll-Free Breast Care Helpline is established to provide assistance to breast cancer patients and families.
“I refer to cancer as an unwanted gift. Cancer changed who I am and altered my perception of life – but all for the better.”

Jessica Winkler
Breast Cancer Survivor

1991
Pink ribbons are distributed for the first time to all breast cancer survivors and participants of the Komen New York City Race for the Cure®.

2000
For the first time in a single season, more than 1 million people cross the finish line in the Susan G. Komen Race for the Cure® Series.

2013
Nearly 3 million people in the U.S. are breast cancer survivors, the largest number of cancer survivors in the U.S.
PARTNERS

Komen corporate partners do more than make donations. They support research and build programs to help women and men in communities they also serve, while engaging their customers and employees in the fight against breast cancer. In 30 years, they have become valued members of the Komen team.

AMERICAN AIRLINES  A Partnership of Promise

American Airlines was one of Komen's very first Race for the Cure sponsors in 1983, and in 2008 became Komen's first Lifetime Promise Partner by funding a $7.5 million Komen Promise Grant to research into inflammatory breast cancer. Komen's hometown airline supports health and community programs through its Miles for the Cure and Celebrity Golf and Tennis events. American is a National Series Sponsor of the Susan G. Komen Race for the Cure and the official airline of the Race for the Cure and the Susan G. Komen organization.

BOWL FOR THE CURE  Striking a Blow Against Breast Cancer

Bowl for the Cure raises awareness and funds year-round through merchandise sales, online donations and Bowl for the Cure events sponsored by the United States Bowling Congress. More than $10 million in funds have been raised through the Bowl for the Cure partnership.

1983

American Airlines becomes one of Komen’s first Race for the Cure National Series sponsors.

2011

A $2 million, three-year partnership with the Caterpillar Foundation is aimed at providing education, training and support for breast cancer programs in low-resource countries in Latin America. It is the largest gift from a single foundation ever awarded in our history.
FORD  Driving Change
Ford has been a champion of the breast cancer cause for more than 18 years as a National Series Sponsor of the Susan G. Komen Race for the Cure. Ford’s Warriors in Pink and Models of Courage programs raise funds, provide information about breast cancer, and honor breast cancer survivors.

NEW BALANCE  A Long-Running Partnership
New Balance was the first company to sponsor every Susan G. Komen national event. New Balance has been a National Series Sponsor of the Susan G. Komen Race since 1991, a National Series Sponsor of the Susan G. Komen 3-Day since 2004 and a founding sponsor of Marathon for the Cure. In addition, New Balance donates 5 percent of sales from its Lace Up for the Cure collection of footwear and apparel, including the official running shoe and the official walking shoe of Susan G. Komen.

ZETA TAU ALPHA  Majoring in Making a Difference
2012 marked the 20th anniversary of Komen’s partnership with the Zeta Tau Alpha women’s fraternity, comprised of 163 college chapters and 242 alumnae groups. Zeta Tau Alpha was the first organization to sponsor Komen’s Breast Cancer Survivor Recognition Program at Komen Races, starting in 1992, providing the signature pink shirts and hats for breast cancer survivors at every Race for the Cure event. For 20 years, Zeta members have volunteered their time for our cause, educating young women and raising awareness in communities around the U.S.

RALLY FOR THE CURE / CONDÉ NAST PUBLICATIONS  FY13 Mission Possible Award Winner
Rally for the Cure/Condé Nast is one of Komen’s longest-running partners and a three-time winner of Komen’s Mission Possible Award, which recognizes the corporate partner making the largest financial donation in any given year. Through local golf, tennis and social events, Rally for the Cure has raised more than $69 million since 1996. Funds are invested in local screening, treatment and support programs and Komen’s national research grants program. Rally has reached nearly 2 million participants in 17 years and in FY 2013, returned more than $4 million to Komen Affiliates for local breast cancer programs.
The end of breast cancer will come in laboratories and communities. For 30 years, Komen has been on the front lines of both. Our Affiliates partner with thousands of community organizations to deliver funds, services and real-time help to women, men and families in communities worldwide. Through the end of our 2013 fiscal year, we had invested more than $1.7 billion in community health programs.

CATERPILLAR FOUNDATION PARTNERSHIP

Impact in Latin America

Ending breast cancer outside the U.S. requires partnerships, especially in low-resource countries. Komen and the Caterpillar Foundation teamed up with a $2 million grant in 2011 to focus on Latin America, where Caterpillar has a large employee base and operations. Since then, Caterpillar has invested another $3 million to expand the program, which serves Brazil, Mexico and Panama. More than nine million people have been reached via public service messaging and other awareness activities, and 25,000 people educated about breast health and breast cancer, including more than 2,000 medical professionals and health educators.

MEXICAN EMBASSY AND CONSULATES PROGRAM

A Passport to Better Health

Latinas in the U.S. are not diagnosed with breast cancer as frequently as other demographic groups, but they are more often diagnosed at a later stage and with tumors that are more difficult to treat. To reach Latinas earlier, Komen and the U.S. Mexican Embassy launched a pilot program in 2011 at consulates in Dallas, Little Rock, San Antonio and San Diego. The program provided more than 1,500 referrals for mammograms, diagnosis, treatment and support.

1990

Komen Affiliates award their first community grants for education, screening and treatment projects.

1999

Komen begins outreach in communities outside the U.S. and now works in partnership in more than 30 other countries funding research and providing support for outreach and screening programs.
2011

Lazos que Perduran, Komen’s new outreach specifically for Latinas, launches with a goal of reducing breast cancer deaths among Latinas through screening and community programs. This program was funded in part by JPMorgan Chase Foundation.

2011

Komen funds a pilot project in St. Louis focused on disparities in breast cancer outcomes for women of color. This augments Komen’s participation in a Chicago program also addressing disparities in outcomes for African American women.
Reducing the Global Cancer Burden

In February 2013, Komen convened a Global Women’s Cancer Summit, hosted by Komen and underwritten by GE healthymagination, to help address a growing global women’s cancer crisis. The Summit was the first to bring together global health, government and non-governmental organizations and leaders such as former First Lady Laura Bush; Julie Gerberding, M.D., MPH, president of Merck Vaccines and former Centers for Disease Control and Prevention director; Sue Siegel, CEO of GE healthymagination; and the Hon. Agnes Binagwaho, M.D., Minister of Health of the Republic of Rwanda.
NATIONAL CAPITAL AREA
COMMUNITY GRANTS

Capital Ideas
Our nation’s capital has the highest incidence and death rates from breast cancer of any city in the United States, exacerbated by a fragmented and often difficult-to-navigate healthcare system for low-income and uninsured women. These challenges extend to the communities in the immediate areas surrounding the District. Komen grants of more than $35 million since 1990 have funded programs to reach, screen and treat women in the District of Columbia, Northern Virginia and Southern Maryland. Komen has also invested more than $22 million in research institutions in the region.

KOMEN ADVOCACY
Advocating for Access
Komen advocates worked with other cancer organizations to maintain and increase funding for government programs serving low-income and uninsured women. These efforts helped to sustain $206 million in federal funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and more than $100 million in state funding (securing the first state appropriations for state-funded programs in Oregon and Florida).
Today’s research leads to tomorrow’s breakthroughs. Komen has funded more breast cancer research than any other non-profit – more than $800 million to date. In FY 2013, Komen was funding 500 active research projects, totaling $300 million.

We fund along the entire continuum of research needs, from understanding causes of breast cancer to prevention, to better screening, and to finding better treatments for metastatic and aggressive disease.

1982
The Susan G. Komen Breast Cancer Foundation awards its first research grant, for $28,000, to MD Anderson Cancer Center and Baylor University Medical Center in Texas.

1991
Komen reaches the $1 million mark in funding of research grants in a single year.

1994
Past Komen grantee (and future Komen Scholar), Mary-Claire King, Ph.D., discovers the gene mutation BRCA1, an indicator of an inherited form of breast cancer.

1998
With support from Komen, the U.S. Postal Service issues the Breast Cancer Research Stamp, the first charity stamp ever offered to generate funding for disease awareness and research.

1999
Telomerase, an enzyme instrumental in a chromosome’s ability to divide and replicate, is discovered by Elizabeth Blackburn, Ph.D., a Komen grantee in 2000 and 2004 who will go on to win the Nobel Prize in Medicine in 2009 for this discovery.
RESEARCH HIGHLIGHTS

Boosting Breakthroughs

In FY 2013, Komen funded $49.5 million in new research.
In the same year:

Komen Scholar Dr. Jennifer Pietenpol of Vanderbilt-Ingram Cancer Center confirms the identification of six distinct subtypes of Triple Negative Breast Cancer (TNBC), based on genetic “fingerprints.” This work, funded by Komen and the Milburn Foundation, will help guide studies to treat three of the six TNBC subtypes.

Komen Scholar Dr. Lori Pierce’s research at the University of Michigan Medical Center leads to a phase I clinical trial into a new drug (PARP inhibitor compound ABT888) for patients with inflammatory breast cancer (IBC).

Dr. Hyman Muss of the University of North Carolina Lineberger Comprehensive Cancer Center is granted the Brinker Award for Scientific Distinction in Clinical Research for his work with older breast cancer patients.

Professor Yosef Yarden of the Weizmann Institute of Science in Israel receives the Brinker Award for Scientific Distinction in Basic Science for his research into targeting growth factor receptors by cancer drugs.

Komen awards $4.5 million in new research grants focused on understanding the role that the environment may play in breast cancer development.

---

2000
Komen introduces Promise Grants – large-scale, multi-million dollar grants to focus intensive, coordinated research efforts on complex issues in breast cancer. The first of these grants, funded by American Airlines, seeks to understand and develop treatments for inflammatory breast cancer.

2007
Komen is a founding member of the International Cancer Research Partnership (ICRP), along with nine other leading cancer funding organizations. ICRP membership will grow to 50 organizations worldwide.

2008
The Susan G. Komen Tissue Bank at Indiana University is established with a $1 million donation from Komen. It is the first repository for healthy breast tissue in the world, offering researchers across the globe new tools to study how cancer develops and spreads.

2008
Komen celebrates $100 million awarded in research grants, the largest single-year investment in research in our history.

2008
Lymphoseek®, an agent which reveals whether breast cancer has spread to lymph nodes, receives FDA approval. In 1999, Komen awarded a grant for a Phase I clinical testing of this agent.

2013
The Susan G. Komen Tissue Bank at Indiana University is established with a $1 million donation from Komen. It is the first repository for healthy breast tissue in the world, offering researchers across the globe new tools to study how cancer develops and spreads.
INTERNATIONAL CANCER RESEARCH PARTNERSHIP
A Major Research Resource

Research is best when it is collaborative. Komen was a founding member of the International Cancer Research Partnership (ICRP), a consortium of 50 leading cancer organizations, dedicated to ensuring greater international collaboration in breast cancer research. In its first report, released in FY 2013, ICRP member organizations reported funding more than 20,000 grants totaling $4.6 to $4.8 billion in one year. Komen chaired this partnership at the time the report was released.
KOMEN ADVOCACY
Advocating for Research Funding

Komen and other cancer organizations’ efforts have helped boost federal breast cancer research budgets by more than 30-fold in 30 years. That advocacy continued in FY 2013, helping to avoid more severe budget cuts for the National Institutes of Health, including the National Cancer Institute, and helping to renew state-funded cancer research programs in California and Texas.
SUSAN G. KOMEN TOTAL SPENDING FISCAL YEAR 2013

*Without value of contributions goods and services.

- **38%** Education
- **20%** Screening
- **18%** Research
- **11%** Fundraising
- **7%** Treatment
- **6%** Admin
# CONSOLIDATED STATEMENT OF ACTIVITIES

## Fiscal Year Ended March 31

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PUBLIC SUPPORT AND REVENUE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions</td>
<td>$165,854,539</td>
<td>$129,664,202</td>
</tr>
<tr>
<td>Race for the Cure and 3 Day Walk Series</td>
<td>257,850,171</td>
<td>208,014,313</td>
</tr>
<tr>
<td>Less: Direct benefit to donors and sponsors</td>
<td>(29,931,680)</td>
<td>(29,244,925)</td>
</tr>
<tr>
<td><strong>NET PUBLIC SUPPORT</strong></td>
<td>$393,773,030</td>
<td>$308,433,590</td>
</tr>
<tr>
<td><strong>REVENUE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investment Income</td>
<td>4,804,885</td>
<td>16,435,382</td>
</tr>
<tr>
<td>Other Income</td>
<td>386,653</td>
<td>333,271</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td>$5,191,538</td>
<td>$16,768,653</td>
</tr>
<tr>
<td><strong>TOTAL NET PUBLIC SUPPORT AND REVENUE</strong></td>
<td>$398,964,568</td>
<td>$325,202,243</td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program Services</td>
<td>$318,281,722</td>
<td>$267,350,171</td>
</tr>
<tr>
<td>Management and General</td>
<td>23,064,504</td>
<td>19,356,330</td>
</tr>
<tr>
<td>Fundraising</td>
<td>52,118,804</td>
<td>50,772,037</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$393,465,030</td>
<td>$337,478,538</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td>$5,499,538</td>
<td>($12,276,295)</td>
</tr>
<tr>
<td><strong>Net assets, beginning of year</strong></td>
<td>193,219,138</td>
<td>198,718,676</td>
</tr>
<tr>
<td><strong>NET ASSETS, END OF YEAR</strong></td>
<td>$198,718,676</td>
<td>$186,442,381</td>
</tr>
</tbody>
</table>

The Consolidated Statements of Financial Position and Activities as reported above have been audited by Ernst & Young, LLP in accordance with auditing standards generally accepted in the United States. To review our complete audited financial statements and the Form 990s filed with the IRS, please visit www.komen.org.
FY 2013 SCIENTIFIC ADVISORY BOARD & KOMEN SCHOLARS

The Scientific Advisory Board (SAB), comprised of world-class leaders in breast cancer research, clinical practice and patient advocacy, provides strategic guidance for Komen in research and scientific programs. The SAB serves as the executive committee of the Komen Scholars.

The Komen Scholars are an advisory group of more than 60 leaders in breast cancer research and patient advocacy who have made and are making significant contributions to advance the field. Komen Scholars advise Komen’s scientific peer review process.

SCIENTIFIC ADVISORY BOARD (EXECUTIVE COMMITTEE)

George Sledge, M.D.
Chief Scientific Advisor
Stanford University

Eric Winer, M.D.
Chief Scientific Advisor
Dana-Farber Cancer Institute

Carlos Arteaga, M.D.
Vanderbilt-Ingram Cancer Center

Myles Brown, M.D.
Dana-Farber Cancer Institute

Powel Brown, M.D., Ph.D.
University of Texas MD Anderson Cancer Center

Karen Gelmon, M.D., FRCPath
University of British Columbia and BC Cancer Agency

Cheryl Jernigan
Komen Advocate in Science

Amelie Ramirez, Dr.PH
University of Texas Health Science Center at San Antonio

KOMEN SCHOLARS

Benjamin Anderson, M.D.
Fred Hutchinson Cancer Research Center

Alan Ashworth, Ph.D., FRS
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research

Sunil Badve, M.D., FRCPath
Indiana University School of Medicine

José Baselga, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Kimberly Blackwell, M.D.
Duke University School of Medicine

Gerard Blobe, M.D., Ph.D.
Duke University School of Medicine

Melissa Bondy, Ph.D.
Baylor College of Medicine

Joan Brugge, Ph.D.
Harvard Medical School

Lisa Carey, M.D.
UNC Lineberger Comprehensive Cancer Center

E. Claire Dees, M.D., Ms.C.
UNC Lineberger Comprehensive Cancer Center

Angelo Di Leo, M.D., Ph.D.
Hospital of Prato, Istituto Toscana Tumorri

Susan Domchek, M.D.
Abramson Cancer Center at the University of Pennsylvania

Mary Elliott
Komen Advocate in Science

Carol Fabian, M.D.
University of Kansas Medical Center

Sandra Finestone, PsyD.
Komen Advocate in Science

Silvia Formenti, M.D.
New York University School of Medicine and Langone Medical Center

William Foulkes, M.B., Ph.D.
McGill University

Patricia Ganz, M.D.
University of California, Los Angeles

Judy Garber, M.D., MPH
Baylor Cancer Center Institute

Ana Gonzalez-Angulo, M.D., M.Sc., FACP
University of Texas MD Anderson Cancer Center

Julie Gralow, M.D.
University of Washington School of Medicine and Seattle Cancer Care Alliance

Joe Gray, Ph.D.
Oregon Health & Science University Knight Cancer Institute

Theresa Guise, M.D.
Indiana University School of Medicine

Susan Hankinson, Sc.D.
University of Massachusetts, Amherst

Daniel Hayes, M.D.
University of Michigan Health System

Mien-Chie Hung, Ph.D.
University of Texas MD Anderson Cancer Center

Nola Hytton, Ph.D.
University of California, San Francisco

Nancy Hynes, Ph.D.
Friedrich Miescher Institute for Biomedical Research

Cheryl Jernigan
Komen Advocate in Science

Peggy Johnson
Komen Advocate in Science

V. Craig Jordan, OBE, Ph.D., D.Sc.
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

Bella Kaufman, M.D.
University of Federation Medical Center

Mary-Claire King, Ph.D.
University of Washington School of Medicine

Ian Krop, M.D., Ph.D.
Dana-Farber Cancer Institute

Beverly Laird, Ph.D.
Komen Advocate in Science

Adrian Lee, Ph.D.
University of Pittsburgh Cancer Institute

David Livingston, M.D.
Dana-Farber Cancer Institute and Harvard Medical School

H. Kim Lyerly, M.D.
Duke University School of Medicine

Eleftherios Mamounas, M.D., MPH
MD Anderson Cancer Center, Orlando

Anne McTieman, M.D., Ph.D.
Fred Hutchinson Cancer Research Center

Funda Meric-Bernstam, M.D.
University of Texas MD Anderson Cancer Center

Kathy Miller, M.D.
Indiana University School of Medicine

Gordon Mills, M.D., Ph.D.
University of Texas MD Anderson Cancer Center

Harikrishna Naskhatri, B.V.Sc. (DVM), Ph.D.
Indiana University School of Medicine

Olufunmilayo Olopade, M.D., FACP
University of Chicago Medical Center

Bert O’Malley, M.D.
Baylor College of Medicine

Ramon Parsons, M.D., Ph.D.
Columbia University

Ann Partridge, M.D., MPH
Dana-Farber Cancer Institute

Rena Pasick, Dr.PH
University of California, San Francisco

Lori Pierce, M.D.
University of Michigan Health System

Jennifer Pietenpol, Ph.D.
Vanderbilt-Ingram Cancer Center

Jeffrey Rosen, Ph.D.
Baylor College of Medicine

Bryan Schneider, M.D.
Indiana University School of Medicine

Christos Sotiriou, M.D., Ph.D.
Jules Bordet Institute

Patricia Spears
Komen Advocate in Science

Neil Spector, M.D.
Duke University School of Medicine

Vered Stearns, M.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Sara Sukumar, Ph.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

William Symmans, M.D.
University of Texas MD Anderson Cancer Center

Thea Tisty, Ph.D.
University of California, San Francisco

Geoffrey Wahl, Ph.D.
The Salk Institute for Biological Studies

Danny Welch, Ph.D.
University of Kansas Medical Center

Julia White, M.D.
The Ohio State University Medical School

Antonio Wolff, M.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Kim Wright
Komen Advocate in Science

Douglas Yee, M.D.
Masonic Cancer Center, University of Minnesota
THANKS FOR MAKING A DIFFERENCE

Komen sponsors, donors and volunteers gave generously in FY 2013, helping us make a difference in the lives of people with breast cancer. Thank you for your support, commitment and belief in our mission.

Komen Million Dollar Council Elite
The sponsors and partners on the Komen Million Dollar Council Elite commit to investing $1 million annually in the fight against breast cancer.

American Airlines
Bank of America
Belk
Ford
GE healthymagination
Merck & Co.
New Balance
Rally for the Cure/Condé Nast
Sally Beauty Supply
The Caterpillar Foundation
Walgreens
World Wrestling Entertainment Corporation (WWE)
Yoplait / General Mills
Zumba Fitness, LLC

Komen Million Dollar Council
The Komen Million Dollar Council is a special group of sponsors, partners and corporate foundations that contribute at least $1 million over time to support our efforts to fight breast cancer on all fronts. These partners engage consumers, associates and civic programs, and we thank them.

Acushnet (Titleist)  MLB
Ask.com  Mohawk
Bowl for the Cure  On the Border
Carlisle  Oreck
DELL  Payless / Collective Brands
Deluxe  Princess Cruises
Energizer  REMAX
Fuze  Triple Negative Breast Cancer Foundation
Genentech Inc.  Tubbs Romp to Stomp
Georgia Pacific  Wacoal
Hallmark  Women in Medicine & Law
KitchenAid  Zeta Tau Alpha
Meredith

MLB
Mohawk
On the Border
Oreck
Payless / Collective Brands
Princess Cruises
REMAX
Triple Negative Breast Cancer Foundation
Tubbs Romp to Stomp
Wacoal
Women in Medicine & Law
Zeta Tau Alpha